Empyrean Capital Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$45.9M |
| 2 |
Option Care Health
OPCH
|
+$20.5M |
| 3 |
Albertsons Companies
ACI
|
+$10.1M |
| 4 |
ATVI
Activision Blizzard
ATVI
|
+$5.75M |
| 5 |
Savers
SVV
|
+$5.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VMW
VMware, Inc
VMW
|
+$135M |
| 2 |
Ashland
ASH
|
+$67.4M |
| 3 |
Ferguson
FERG
|
+$39.2M |
| 4 |
Liberty Global Class C
LBTYK
|
+$35.1M |
| 5 |
APA Corp
APA
|
+$31.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 25.34% |
| 2 | Industrials | 21.02% |
| 3 | Energy | 12% |
| 4 | Technology | 10.84% |
| 5 | Financials | 9.46% |
Similar funds
Empyrean Capital Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Empyrean Capital Partners held 91 positions worth $2.21B, down 24% from $2.92B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Empyrean Capital Partners withdrew a net $806M in Q2 2023, closing 22 positions and reducing 13 holdings. Its most notable exit was Ashland, an estimated $67.4M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 25% a quarter earlier, followed by Industrials and Energy.
Against the trend, Empyrean Capital Partners opened a new position in Seagen Inc. Common Stock worth $44.5M.
- Empyrean Capital Partners's largest Q2 2023 buy was Seagen Inc. Common Stock: 231,000 shares worth $44.5M.
- Empyrean Capital Partners added most to Albertsons Companies in Q2 2023, an estimated $10.1M increase.
- Empyrean Capital Partners's biggest Q2 2023 reduction was VMware, Inc, cutting an estimated $135M.
- Empyrean Capital Partners fully exited Ashland in Q2 2023, selling an estimated $67.4M.
- Empyrean Capital Partners's ten largest holdings make up 52% of its $2.21B portfolio in Q2 2023.
- Empyrean Capital Partners opened 5 new positions and closed 22 in Q2 2023.
- Empyrean Capital Partners's portfolio value fell 24% quarter-over-quarter to $2.21B.
Based on Empyrean Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.